Knowledge Library
Discovery Newsletter November 2022
PD-1 Blockade Protein in 4th Generation Armored CAR-T Cells Enhances Cytotoxicity Effect with in vitro Re-challenge System
Chimeric antigen receptor (CAR)-T cells are genetically engineered T cells that express a surface receptor to recognize tumor-associated antigens (TAA). CAR-T cell therapy have demonstrated remarkable success with hematological malignancies. However, limited headway has been made towards solid tumor, due to various challenges, including recognition of tumor-specific antigen trafficking and penetration, localization and survival within …Read More >
WuXi AppTec Discovery Services
Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platform. Integrated Chemistry and Biology Research Platform | From Discovery to Candidate Selection and Beyond
Drug Hunter: Discovering New Frontiers in Cancer Treatments & Beyond
INNOVATION THAT MATTERS By Rich Soll, Senior Advisor, Strategic Initiatives at WuXi AppTec (@richsollwx) As a self-proclaimed drug hunter, Phil Jones is on a mission to identify the next generation of cancer medicines that improve the lives of patients with cancer. He leads a multi-disciplinary team of scientists at The University of Texas MD Anderson Cancer Center’s Institute …Read More >
CAR-T TCR-T
Integrated Platforms To Accelerate CAR-T/TCR-T Programs Comprehensive target validation program OXGENE based target expression system ensure high-efficiency delivery Systematic in vitro functional & safety assays in vivo efficacy studies Well-established genomic editing technology in primary immune cells
Virology and Viral Vector Platforms
WuXi virology platforms: Immunology, Anti viral, Viral Vector, Oligo-nucleotide, Clinical and Immunology in vitro screening and profiling in vivo efficacy clinical virology Liver-specific viruses | Respiratory viruses | Herpes viruses | Other viruses